Cargando…

Germline Polymorphisms as Biomarkers of Tumor Response in Colorectal Cancer Patients Treated with Anti-EGFR Monoclonal Antibodies: A Systematic Review and Meta-Analysis

Studies of germline polymorphisms as predictors of tumor response to anti-EGFR monocloncal antibody agents in metastatic colorectal cancer have reported inconsistent results. We performed a systematic review of studies from 1990 to September, 2015, followed by random-effects meta-analyses for polymo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgen, Eric K, Lenz, Heinz-Josef, Jonker, Derek J, Tu, Dongsheng, Milano, Gerard, Graziano, Francesco, Zalcberg, John, Karapetis, Christos S, Dobrovic, Alexander, O’Callaghan, Chris J, Liu, Geoffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536193/ https://www.ncbi.nlm.nih.gov/pubmed/27897268 http://dx.doi.org/10.1038/tpj.2016.56

Ejemplares similares

Fc‐gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer
por: Shepshelovich, Daniel, et al.
Publicado: (2018)

Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
por: Zhang, Jiahui, et al.
Publicado: (2022)

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
por: Mellor, James D, et al.
Publicado: (2013)

Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

Two-stage multivariate Mendelian randomization on multiple outcomes with mixed distributions
por: Deng, Yangqing, et al.
Publicado: (2023)

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'
por: Rowland, Andrew, et al.
Publicado: (2015)

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
por: Jonker, D J, et al.
Publicado: (2014)

Germline EGFR mutations in lung cancer (Review)
por: Liu, Minghui, et al.
Publicado: (2023)

Anti-VEGF and anti-EGFR agents open up new horizons changing the landscape for their associations
por: Milano, Gerard
Publicado: (2016)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial
por: Hoch, Jeffrey S., et al.
Publicado: (2019)

Early detection of treatment futility in patients with metastatic colorectal cancer
por: Rattner, Jodi I., et al.
Publicado: (2022)

Clinical and metabolomic characterization of Brivanib‐Induced hypertension in metastatic colorectal cancer
por: Rattner, Jodi I., et al.
Publicado: (2023)

Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting
por: O'Callaghan, Christopher A, et al.
Publicado: (2011)

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
por: Patel, Gargi S, et al.
Publicado: (2015)

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer
por: Sebio, Ana, et al.
Publicado: (2015)

EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies
por: Derer, Stefanie, et al.
Publicado: (2013)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
por: Mäkinen, Netta, et al.
Publicado: (2021)

Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset
por: Ruseckaite, Rasa, et al.
Publicado: (2016)

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer
por: Topham, James T., et al.
Publicado: (2023)

Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial
por: Fontana, Elisa, et al.
Publicado: (2020)

Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer
por: Burr, Risa, et al.
Publicado: (2023)

Familial Myelodysplastic/Acute Leukemia Syndromes—Myeloid Neoplasms with Germline Predisposition
por: Baptista, Renata Lyrio Rafael, et al.
Publicado: (2017)

The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report
por: Liu, Bin, et al.
Publicado: (2021)

Exosomes from EGFR-Mutated Adenocarcinoma Induce a Hybrid EMT and MMP9-Dependant Tumor Invasion
por: Jouida, Amina, et al.
Publicado: (2022)

Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials
por: Wells, J Connor, et al.
Publicado: (2022)

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
por: Concha-Benavente, Fernando, et al.
Publicado: (2017)

Nimotuzumab, an Anti-EGFR Monoclonal Antibody, in the Treatment of Nasopharyngeal Carcinoma
por: Liang, Renba, et al.
Publicado: (2021)

EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment
por: Guérin, Olivier, et al.
Publicado: (2010)

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
por: Ferris, Robert L., et al.
Publicado: (2017)

A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms
por: Jin, Yu-jia, et al.
Publicado: (2021)

Novel EGFR V834L Germline Mutation Associated With Familial Lung Adenocarcinoma
por: van der Leest, Cor, et al.
Publicado: (2018)

Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
por: Sagan, Olivia A., et al.
Publicado: (2023)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

Elucidation of the critical epitope of an anti-EGFR monoclonal antibody EMab-134
por: Kaneko, Mika K., et al.
Publicado: (2018)

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
por: Cai, Wen-Qi, et al.
Publicado: (2020)

The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022)

EGFR Q787Q Polymorphism Is a Germline Variant and a Prognostic Factor for Lung Cancer Treated With TKIs
por: Wu, Wen-Jui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lqvncjrs8t3v5rdkni4qd11im1